NZ237975A - Granulocyte stimulating factor (g-csf) variants with modifications to residues 50-59 or at least of the his residues, production using recombinant techniques and pharmaceutical compositions - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £37975 Comptc^ ** • ' "liass: .. - . ■ ^jbHcn "• P*ic: . P.O. AN*: !t-5S€-P--»9?2 1 3 1 iW .fS * In?* 23 7 9 NEW ZEALAND PATENTS ACT. 1953 No.: Date: ,-.~c COMPLETE SPECIFICATION MOTBINS OP THE GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ^/We. BOEHRINGER MANNHEIM GmbH, a German corporation, of Sandhofer Strasse 112-132, D-6800 Mannheim - Waldhof, Germany hereby declare the invention for which Z / we pray that a patent may be granted to me/us, and the method by which it is to be performed, to be particularly described in and by the following statement: - (followed bv naae la) 23 7 9 Descript ion The invention concerns inuteins of the granulocyte stimulating factor G-CSF in the sequence 50 51 52 53 54 55 56 Leu-Gly-His-Ser-Leu-Gly-Ile at position 50 to 56 of the mature G-CSF with 174 amino acids or at position 53 to 59 of the mature G-CSF with 177 amino acids or/and at least one of the 4 His residues at positions 43, 79, 156 and 170 of the mature G-CSF with 174 amino acids or at positions 46, 82, 159 or 173 of the mature G-CSF with 177 amino acids.

Lymphokines are involved in the maturation of blood cells. They stimulate the maturation of bone marrow stem cells to fully differentiated cells. G-CSF is synthesized by activated monocytes, macrophages as well as by a series of other cell lines.

G-CSF was purified to homogeneity from cell culture supernatants of the human bladder carcinoma cell line 5637 (Welte et al., Proc. Natl. Acad. Sci 82 (19S5), 1526). The sequence of the cDNA coding for native G-CSF is known from Sunza et al., Science 232 (1986), 61. As a consequence of alternative splicing in the second intron two naturally occurring forms of G-CSF exist with 204 or 207 amino acids of which the first 30 represent a signal peptide (Lymphokines, IRL Press, Oxford, Washington D.C., Editors D. Male and C. Rickwood). The mature protein has a molecular weight of ca.19.6 kD and has 5 cysteine residues which can form intermolecular or intramolecular disulphide bridges. Binding studies have shown that G-CSF binds to neutrophilic granulocytes.

None or only slight binding is observed with erythroid, lymphoid eosinophilic cell lines as well as with macrophages. The G-CSF receptor consists of a single peptide chain with a molecular weight of 150 kD (Nicola, Immunol. Today 8 (1987), 134). The number of receptors per cell generally increases with the maturation of the cells and can amount to several hundred per cell. It is assumed that lymphokine receptors consist of an extracellular domain, which binds the ligands, a hydrophobic transmembrane region and an intracellular domain. Binding of lymphokines to their receptor can cause the synthesis of cyclic nucleotides, hydrolysis of phosphatidylinositol-4,5-biphosphate as well as the activation of protein kinase C and an increase in the intracellular calcium level. There is a great interest in how these processes effect the metabolism of the cell but at present they are hardly understood. A further result of the binding of a ligand to its receptor can be the migration of the receptor-ligand complex into the inside of the cell by a receptor-dependent enaocyrosis. This type of internalization apparently also occurs with lymphokines (e.g. G-CSF), however, the consequences for the metabolism of the cell are not yet understood- Since G-CSF is able to substantially increase the population of neutrophilic granulocytes within a short period, considerable therapeutic fields of application arise for G-CSF. Thus, G-CSF could be used e.g. after chemotherapy in cancer, in which the cells of the immune system are destroyed. In addition G-CSF could be used in bone marrow transplantations, in severe burn wounds, in opportunistic infections caused by immune deficiency and in leukemia. For the different types of therapy it would be desirable to develop more active and also less active forms of G-CSF. The object of the present invention is therefore to develop G-CSF molecules with a wide 237 9 r> spectrum of activity by the specific introduction of point mutations. In this process the changes in activity should be achieved by changes in the amino acid sequence which are as small as possible.

The object according to the present invention is achieved by a granulocyte stimulating factor (G-CSF) or a G-CSF variant, in which one or several amino acids of the sequence Leu-Gly-His-Ser-Leu-Gly-Ile at position 50 to 56 of the mature G-CSF with 174 amino acids or at position 53 to 59 of the mature G-CSF with 177 amino acids or/and at least one of the 4 His residues at position 43, 79, 156 or 170 of the nature G-CSF with 174 amino acids or at position 46, 82, 159 or 173 of the mature G-CSF with 177 amino acids are mutagenized.

Surprisingly the introduction of new amino acids yields G-CSF muteins which have a broad spectrum of activity. The determination of the activity can for example be carried out according to Biochem- J. 253 (1988) 213-218; Exp. Henatol. 17 (1989) 116-119; Proc. Natl. Acad. Sci. USA 83 (1986) 5010.

The term G-CSF or G-CSF variant according to the present invention includes all naturally occurring variants of G-CSF with or without a leader sequence as well as G-CSF proteins derived therefrom which are modified by recombinant DNA technology, in particular fusion proteins which contain further polypeptide sequences apart from the G-CSF moiety. In this sense a G-CSF mutein is particularly preferred with a N-terminal Met residue at position -l which is suitable for expression in prokaryotic cells. Also preferred is a recombinant, methionine-free G-CSF variant which can be produced according to PCT/EP 91/00 192. The term "mutagenized" means that the respective amino acid is deleted or preferably substituted by another amino acid.

In this sense G-CSF nuteins are preferred in which one of the 7 amino acids of the sequence Leu-Glv-His-Ser-Leu-Gly-Ile is substituted by another amino acid. However, more than one, in particular two amino acids, can also be replaced.

A G-CSF inutein is particularly preferred in which the Ser residue at position 53 of the mature G-CSF with 174 amino acids or at position 56 of the mature G-CSF with 177 amino acids is replaced by one of the other 19 amino acids, in particular by Thr.

Furthermore, it is preferred that the Leu residue at position 54 of the mature G-CSF with 174 amino acids or at position 57 of the mature G-CSF with 177 amino acids is substituted by one of the 19 other amino acids, in particular by Thr. By this means one obtains G-CSF muteins with a broad variation of G-CSF activity.

In addition G-CSF muteins are preferred in which one of the 4 His residues at position 43, 79, 156 or 170 of the mature G-CSF with 174 amino acids or at position 46, 82, 159 or 173 of the mature G-CSF with 177 amino acids is substituted by another amino acid, in particular Gin.

The invention also provides a recombinant DNA which codes for a G-CSF mutein according to the present invention. The invention also provides a recombinant vector which contains at least one copy of a recombinant DNA according to the present invention. In this connection a recombinant vector is preferred, which is 23 7 3 suitable for gene expression in prokaryotic cells. Vectors of this type are known to one skilled in the art.

In addition the invention provides a cell which is transformed with a recombinant DNA according to the present invention or/and a recombinant vector according to the present invention. This cell is preferably a prokaryotic cell, particularly preferably an E. coli cell.

The invention also provides a process for the production of a recombinant DNA according to the present invention in which a DNA sequence which codes for G-CSF or a G-CSF variant is site-specifically mutagenized. The usual molecular-biological methods for site-specific mutagenesis are known to one skilled in the art. The mutagenesis is preferably carried out by using synthetic oligonucleotides as mutagenesis primers on single-stranded DNA as the template. Common methods are for example described in Amersham No. 1523 "Oligonucleotide-directed in vitro mutagenesis system"; Methods in Enzymology (Academic Press, Inc. Vol. 154, Part £, 367-382 (1987); Analytical Biochemistry 179 (1989) 309-311.

In addition the invention provides a process for producing a G-CSF mutein according to the present invention in which a cell is transformed with a recombinant DNA according to the present invention or/and a recombinant vector according to the present invention, the transformed cell is cultured in a suitable medium and the protein is isolated from the cells or the medium. The methods usually used in molecular biology for the isolation of recombinant proteins from eukaryotic or prokaryotic cells are known 23 7 9 7 to one skilled in the art and do not need to be elucidated in detail.

Finally the invention also provides a pharmaceutical preparation based on a G-CSF mutein according to the present invention as the active substance, if desired, together with the usual pharmaceutical carrier, filling and auxiliary substances. Such a pharmaceutical preparation is particularly suitable for the therapeutic fields of application mentioned above and even for further therapeutic proceedures in which the formation of neutrophilic granulocytes is to be stimulated.

The following examples are intended to elucidate the invention without however limiting its scope.

Example 1 Production of the vector mql-G-CSF-3g The 554 bp long EcoRI/BamHI fragment from the vector pKK 177-3 G-CSF-Bg (DSM 5867) containing the Shine Dalgarno sequence, ATG codon and coding sequence for the G-CSF gene is cloned via a blunt-end ligation into the Ncol cleavage site of the vector pPZ 07-mgl lac (W08S/09373, Figure 10) . The ATG start codon of the lac Z gene, which is located in the protruding single strand after Ncol digestion, is digested beforehand by incubation with mung bean nuclease (Pharmacia). The resulting vector is denoted mgl-G-CSF-Bg. 237 9 7 Example 2 """N Mutagenesis of the amino acid Leu in the sequence ~ Glv-His-Ser-Leu-Glv—lie The mutagenesis is carried out on the M13 template according to known techniques (Amersham No. 1523 "Oligonucleotide-directed in vitro mutagenesis system") .

A 251 bp long G-CSF cDNA fragment is isolated via the cleavage site BstXI/Aatll. The protruding single-strands are digested off by mung bean nuclease (Pharmacia) and the fragment is cloned into the vector M13mpl9 which was cleaved with EcoRI/Smal (EcoRI protruding single strand was filled in for blunt-end cloning). After preparing single-stranded DNA, the oligonucleotide is hybridized to the single-stranded DNA and an elongation in the 5*— 3' direction beyond the oligonucleotide is carried out using Klenow polymerase, ligase and the four nucleotide triphosphates (GTP, CTP, TTP, ATP) . The DNA which is now double-stranded is transformed in E. coli cells which carry a F* episome so that infection by filamentous M13 phages is possible (e.g. JM101, obtainable from Stratagene, LaJolla, California)- Individual plaques are picked out and the mutagenized M13 phages contained therein are used for the preparation of single-stranded DNA. A DNA sequencing is carried out according to known techniques (e.g. dideoxy method according to Sanger) and the exact substitution to form the desired mutation is checked in this way. After preparing double-stranded DNA the mutated Aval fragment of G-CSF is isolated and cloned in the expression vector ragl-G-CSF-Bg (cleaved with Aval).

In order to reconstitute the complete G-CSF gene the DNA is subsequently cleaved with Hindlll, the protruding ends are filled in with Klenow polymerase and afterwards partially digested with Aval so that the 5* Aval site in the G-CSF gene (at ca 130 bp) is not cleaved. This DNA is ligated with the approximately 240 bp G-CSF fragment Aval/BamHI (BamHI site is filled in with Klenow polymerase) from the starting vector mgl-G-CSF-Bg.

After transformation in E. coli JM83, the expression of G-CSF is carried out in the manner described in W088/0937 3.

The cDNA used has a sequence which codes for a G-CSF with 175 amino acids (without a signal sequence, but with a Met residue at position -1) so that the preferred mutation is located at Leu at position 54 of the G-CSF amino acid sequence (in this the N-terminal Met residue is not counted).

The sequence of the cDNA encoding G-CSF which codes for the amino acids 50 to 56 (with reference to the G-CSF with 174 amino acids) reads: (X) Leu-Gly-His-Ser-Leu-Gly-Ile 5 *—CTC GGA CAC TCT CTG GGC ATC-3' The corresponding complementary opposite strand to be mutagenized reads: '-GAT GCC CAG AGA GTG TCC GAG-3' 237 The following 19 oligonucleotides corresponding to the opposite strand are used for site-directed mutagenesis Wild-type: 5'-3 GAT GCC CAG AGA GTG TCC GAG 3' Met 1. 5* GAT GCC CAT AGA GTG TCC GAG 3* Phe 2. 5* GAT GCC GAA AGA GTG TCC GAG 3' Gin 3. 5' GAT GCC CTG AGA GTG TCC GAG 3* Glu 4- 5' GAT GCC CTC AGA GTG TCC GAG 3' Asp . 5' GAT GCC GTC AGA GTG TCC GAG 31 Cys 6- 5' GAT GCC GCA AGA GTG TCC GAG 3' Ala 7. 5' GAT GCC GGC AGA GTG TCC GAG 3* Gly 8. 5' GAT GCC AGG AGA GTG TCC GAG 3 ' Kis 9 - 5' GAT GCC GTG AGA GTG TCC GAG 3 ' .

He ' GAT GCC GAT AGA GTG TCC GAG 3* 237 Lys 11. 5' GAT GCC CTT AGA GTG TCC GAG 3' Tyr 12. 5' GAT GCC ATA AGA GTG TCC GAG 3* Asn 13- 51 GAT GCC GTT AGA GTG TCC GAG 3* Pro 14. 51 GAT GCC GGG AGA GTG TCC GAG 3' Arg . 5' GAT GCC GCG AGA GTG TCC GAG 3» Ser 16. 5' GAT GCC GGA AGA GTG TCC GAG 3' Thr 17. 51 GAT GCC GGT AGA GTG TCC GAG 3* Val 18. 5' GAT GCC GAC AGA GTG TCC GAG 3' Trp 19. 5' GAT GCC CCA AGA GTG TCC GAG 3' Example 3 Production of a G-CSF with modified activity A G-CSF which is more enzyciatically active compared to the wild-type can be produced by substituting serine a position 53 by a threonine at position 53 of a G-CSF with 174 amino acids (serine in the sequence Gly-His- 23 7 9 . n - Ser-Leu-Gly) . The following double-stranded oligonucleotide was used for the mutagenesis: His Thr Leu Gly He CCC GAG GAG CTG GTG CTG CTC GGA CAC ACC CTG GGC ATC CCC TGG GCT CCC CTG AGC 3 C CTC GAC CAC GAC GAG CCT GTG TGG GAC CCG TAG GGG ACC CGA GGG GAC 5' For the cloning, the G-CSF cDNA fragment (ca 3 00 bp, EcoRI/EcoRV) from the vector pKK 177-3 G-CSF-Bg (DSM 5867) was ligated into the EcoRI/Smal cleavage site of the vector pUC19 (Yannish-Perron et al., (1985), Gene 33, 103).

This DNA is cleaved with Aval/Sac! and directly ligated with the primer pair described above according to the usual techniques. The nutated BstJX/SacI fragment can now be isolated froa this construct and cloned into the vector pKK 177-3 G-CSF-3g (DSM 58 67) (cleaved with BstXI/SacI) . The final construction of the expression clone is carried out in analogy to Example 1. The determination of activity is carried out as described in Example 5.

Example 4 Alteration of the enzvmatic properties of G-CSF bv mutation of amino acids which are not located in the active centre.

In analogy to known serine esterases it is assumed that the serine of the active centre interacts with histidine for the development of enzymatic activity. Four histidines are present in the sequence of G-CSF and namely at positions 43, 79, 156 and 170 (numbered from 237 9 the 174 aa sequence without a signal peptide). The histidine residue at position 52 (or at position 55 in the 177 amino acid form) is left out of consideration in this mutagenesis. In this process His (CCA, CTA) is substituted by Gin (CAG). The sequence on the opposite strand corresponding to the codon coding for Gin is CTG.

A G-CSF fragment is subcloned in Ml3mpl9 as described in Example 1.

The following oligonucleotides corresponding to the opposite strand are used for the mutagenesis: 1. 5' GCT CCT GGG CTG GCA CAG C 3' histidine 43 to glutamine 43 2. 5' GAA AAG GCC GCT CTG GAG TTG GCT C 3' histidine 79 to glutamine 79 3. 5' GCT CTG CAG CTG GCC TAG CAA CC 3» histidine 156 to glutamine 156 4. 5' GGG CTG CGC AAG CTG GCG TAG AAC G 3' histidine 170 to glutamine 170 The analytical procedure and the recloning in an expression vector is carried out in analogy to Example 1. 23 7 9 7 Example 5 Determination of "the G-CSF activity The activity of G-CSF is tested with the murine leukaemia line NSF60 which is completely dependent on G-CSF as described in Biochem. J. 253 (1988) 213-218, Exp. Hematol. 17 (1989) 116-119, Proc. Natl. Acad. Sci. USA 83 (1986) 5010. In order that the factor-dependency of the cells is preserved, the medium (RPMI medium, Boehringer Mannheim GmbH, Order No. 2099445 with 10 % foetal calf serum) for the maintenance culture permanently contains 1000 U/ml G-CSF.

The proliferation of the NSF60 cells stimulated by G-CSF is measured directly in this test by the incorporation of 3H thymidine. The test is carried out as follows: NSF60 cells which are in the exponential growth phase (cell density is maximally lxlO5 cells/ml) are transferred to microtitre plates (lxlO4 cells/well) and cultured with a decreasing G-CSF concentration. The maximum dose of G-CSF in well 1 corresponds to the concentration in the maintenance culture (1000 U/ml, specific activity 1x10s U/mg protein). The dilution is carried out in steps of ten.

After about 24 hours incubation 3H thymidine (0.1 jiCi/well) is added. Afterwards the cells are incubated for a further 16 hours.

In order to evaluate the test the cells in the microtitre plates are frozen in order to lyse them. The cell lysate is aspirated on a glass fibre filter,

Claims (7)

1. 23 7 9 - 14 - rinsed, dried and measured in a scintillation counter-The incorporation of 3H thymidine is proportional to the G-CSF-induced proliferation of the NSF60 cells. Example 6 Alteration in the activity of G-CSF bv amino acid substitution in the active centre A G-CSF modified in amino acid position 54 can be produced by substitution of preferably one leucine at position 54 by a threonine at position 54 (Leu in the sequence Gly-His-Ser-Leu-Gly) in correspondence with the procedure described in Example 3 using a suitable double-stranded oligonucleotide which contains a nucleic acid triplet (e.g. ACC) coding for the amino acid Thr at the appropriate position. In this connection position 54 of the 174 amino acid form of G-CSF corresponds to position 57 of the 177 amino acid form. The activity of a mutant having 174 amino acids with Thr ^ at position 54 is reduced in the NSF60 cell test (see Example 5) in comparison to the wild-type G-CSF with 174 amino acids. Moreover, the activity of this G-CSF mutant is reduced in comparison to a G-CSF mutant with an amino acid substitution of a serine by a threonine at position ^ 53 (described in Example 3). 23 7 9 - 15 -€—jr a i m -a- WHAT tfWE CLAIM IS: 1- Granulocyte stimulating factor (G-CSF) or G-CSF variant, wherein one or several amino acids of the sequence 50 51 52 53 54 55 56 Leu-Gly-His-Ser-Leu-Gly-Ile at position 50 to 56 of the mature G-CSF with 174 amino acids or at position 53 to 59 of the mature G-CSF with 177 amino acids or/and at least one of the 4 His residues at position 43, 79, 156 or 170 of the mature G-CSF with 174 amino acids or at position 46, 82, 159 or 173 of the mature G-CSF with 177 amino acids are mutagenized.

2. G-CSF mutein as claimed is claim l, wherein it contains a N-terminal Met residue at position -1.

3. G-CSF mutein as claimed in claim 1 or 2, wherein one amino acid of the sequence Leu-Gly-His-Ser-Leu-Gly-Ile is substituted by another amino acid. 4- G-CSF mutein as claimed in one of the claims 1 to 3, wherein the Ser residue at position 53 of the mature G-CSF with 174 amino acids or at position 56 of the mature G-CSF with 177 amino acids is substituted by another amino acid. 5. G-CSF mutein as claimed in claim 4, herein the other amino acid is Thr- 237 9 - 16 - 6. G-CSF mutein as claimed in one of the claims 1 to 3, wherein the Leu residue at position 54 of the mature G-CSF with 174 amino acids or at o position 57 of the mature G-CSF with 177 amino acids is substituted by another amino acid. 7. G-CSF mutein as claimed in claim 6, wherein ^ the other amino acid is Thr. 8. G-CSF mutein as claimed in claim l or 2, wherein one of the 4 His residues at position 43, 79, 156 or 170 of the nature G-CSF with 174 amino acids or at position 46, 82, 159 or 173 of the mature G-CSF with 177 amino acids is substituted by another amino acid. 9. G-CSF mutein as claimed in claim 8, wherein the other amino acid is Gin. * 10- Recombinant DNA, wherein it codes for a G-CSF mutein as claimed in one of the claims 1 to 9- 11. Recombinant vector, wherein it contains at least one copy of a recombinant DNA as claimed in claim 10. 12. Recombinant vector as claimed in claim 11, wherein it is suitable for gene expression in prokaryotic cells. >379 13. o 1

4. 1

5. 1

6. 1

7. .O ■% 18- 19. Cell, wherein it is transformed with a recombinant DNA as claimed in claim 10 or/and a recombinant vector as claimed in claim 11 or 12. Cell as claimed in claim 13, wherein it is a prokaryotic cell. Process for the production of recombinant DNA as claimed in claim 10, wherein a DNA sequence which codes for G-CSF or for a G-CSF variant is site-specifically mutagenized. Process as claimed in claim 15, wherein synthetic oligonucleotides are used as mutagenesis primers. Process for the production of a protein with G-CSF activity as claimed in one of the claims 1 to 9, wherein a cell is transformed with a recombinant DNA as claimed in claim 10 or/ana a recombinant vector as claimed in claim 11 or 12, the transformed cell is cultured in a suitable medium and the protein is isolated from the cells or from the medium. Pharmaceutical preparation, characterized by one or several G-CSF muteins as claimed in one of the claims l to 9 as the active substance, if desired, together with the usual pharmaceutical carrier, filling and auxiliary substances. Use of a G-CSF mutein as claimed in any one of claims 1 to 9 in the preparation of a medicament for iscmiiiiotherapy. t - 18 - 237975 O 20. Granulocyte stimulating factor (G-CSF) or G-CSF variant as defined in claim 1 substantially as herein described with reference to any example thereof. 21. A recombinant vector as defined in claim 11 substantially as herein described with reference to any example thereof. 22. A cell as defined in claim 13 substantially as herein described with reference to any example thereof. 23. A process as defined in claim 15 or claim 17 substantially as herein described with reference to any example thereof. 24. A pharmaceutical preparation substantially as herein described with reference to any example thereof. COEHfijfOGre^Z. rAfVfOrOHB iM By ,H«s/Thc;: authorise- Agent A.J, PARK &. SON pen